Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies
Open Access
- 15 December 2020
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 10 (8) , e254
Abstract
Background: Gastric cancer (GC) is confronted with limited options for precision medicine. Human epidermal growth factor receptor 2 (HER2) is the principal druggable target of GC, yet proper biomarkers for response/resistance prediction remain unveiled.Methods: From 40 GC patients received HER2‐targeted therapy, a total of 327 peripheral blood plasma specimens was collected including baseline and treatment time points. Circulating tumor DNA (ctDNA) was extracted and sequenced with a target panel of 425 genes. Experimental validation of resistant mutations was carried out in NIH‐3T3 cell line.Results: Genomic features, includingERBB2copy number variation (CNV), total copy number load, and tumor mutation burdens (TMBs), dynamically changed along with the treatment process and correlated with disease progression. Plasma ctDNA‐based diagnosis was more sensitive than conventional computed tomography scanning in 40% of investigated patients, gaining additional time for clinical management. Compared to baseline, new gene alterations were emerged in 12 patients who developed drug resistance during treatment.ERBB2mutations potentially related to Pyrotinib resistance were identified in plasma ctDNA of one patient and functional analysis of their downstream signaling pathways was carried out in NIH‐3T3 cell line. TMB exhibited more power thanERBB2CNV in predicting treatment responses and prognosis for HER2‐targeted therapy in GC patients. Interestingly, survival analysis indicated that patients harboring both HER2 (ERBB2) positivity and high TMB might gain more therapeutic benefits from immune checkpoint inhibitors instead of HER2‐targeted regimens that required further studies and validationsConclusions: Our work showed that the dynamic surveillance of plasma ctDNA genomic features provided instructive information for the precision medication of GC patients.Keywords
Funding Information
- National Basic Research Program of China (2018YFC1313304)
- National Natural Science Foundation of China (81802327, 81872341)
This publication has 61 references indexed in Scilit:
- Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancerGastric Cancer, 2014
- Copy number alteration burden predicts prostate cancer relapseProceedings of the National Academy of Sciences, 2014
- Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resectionAnnals of Surgical Treatment and Research, 2014
- The role of CT and staging laparoscopy in the staging of gastric cancerClinical Radiology, 2013
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast CancerCancer Discovery, 2013
- Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2Proceedings of the National Academy of Sciences, 2012
- Combining immunotherapy and targeted therapies in cancer treatmentNature Reviews Cancer, 2012
- Differential Sensitivity of ERBB2 Kinase Domain Mutations towards LapatinibPLOS ONE, 2011
- High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic TherapyClinical Cancer Research, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010